Loading…
Underlying
Underlying Price
$6.01
Type
Call
Strike
7
Expiration
Dec 11, 2026
DTE
28d
Moneyness
OTM
Intrinsic
$0.00
IBRX 7 Call Across Expirations
| Expiration | DTE | Last | Change | Vol | Open Int |
|---|---|---|---|---|---|
| Nov 13, 2026 | 0d | $1.49 | -17.22% | 6 | 1,256 |
| Nov 20, 2026 | 7d | $1.50 | -21.05% | 6 | 2,283 |
| Nov 27, 2026 | 14d | — | — | 0 | 41 |
| Dec 4, 2026 | 21d | — | — | 0 | 11 |
| Dec 11, 2026 | 28d | — | — | 0 | 45 |
| Dec 18, 2026 | 35d | $1.85 | +12.12% | 10 | 392 |
| Dec 24, 2026 | 41d | — | — | 0 | 11 |
| Dec 31, 2026 | 48d | — | — | 0 | 0 |
| Mar 19, 2027 | 126d | $2.65 | -5.36% | 5 | 590 |
| Apr 16, 2027 | 154d | $2.65 | -40.85% | 5 | 141 |
| May 21, 2027 | 189d | $2.64 | +10.00% | 5 | 100 |
| Aug 20, 2027 | 280d | $3.60 | +2.86% | 7 | 401 |
| Nov 19, 2027 | 371d | $3.43 | -7.30% | 1 | 557 |
| Mar 17, 2028 | 490d | $4.70 | +32.39% | 2 | 931 |
| Jan 19, 2029 | 798d | $4.40 | -9.47% | 1 | 494 |
IBRX Profile
immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.